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We describe a patient with end stage renal failure (ESRF) on hemodialysis who was admitted to our department for
primary varicella infection complicated by varicella pneumonia and encephalitis. Varicella infections results in serious
morbidity and mortality in ESRF dialysis and transplant patients. Evidence published thus far suggests that live
attenuated varicella vaccines are effective and safe in ESRF and renal transplant patients. Worldwide a few countries
have instituted guidelines for the varicella immunisation in ESRF patients. However, in the Asia Pacific Region, it has
not been widely given due to the lack of national consensus guidelines. Our case depicts that primary varicella
infection can occur at any time in immunosupressed patients and thus suffer serious consequences from it. With
increasing burden of chronic kidney disease, Renal Physicians and Family Physicians in the Asia Pacific Region
should meet and study the epidemiological data in each individual country and decide on the consensus
guidelines on how the varicella vaccination can be targeted for those at risk.
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Our case report illustrates the serious complications of
varicella in a patient with end stage renal failure and em-
phasizes the need for consensus guidelines on varicella
vaccinations in such patients in the Asia Pacific region.
Although evidence in literature show that live attenuated
vaccines can be safe & effective, these vaccines are still
generally avoided due to lack of consensus guidelines on
vaccinations in patients with end stage renal failure. Lit-
erature review provides evidence on the safety and effi-
cacy of varicella vaccination in end stage renal failure
patients. With the increasing burden of chronic kidney
disease, family physicians also need to be alert for these
complications of varicella and can play a big role in fa-
cilitating varicella vaccination in patients with end stage
renal failure.Case presentation
Our patient is a 58 year old construction supervisor with
background of hypertension and ESRF on haemodialysis
three times per week. He was admittted via the Accident* Correspondence: low.lian.leng@sgh.com.sg
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reproduction in any medium, provided the orand Emergency Department to Singapore General
Hospital Department of Family Medicine and Con-
tinuing Care for fever, chills and non productive cough of
two days duration. There was no travel or contact history.
On examination, he was alert, non-toxic looking and ori-
entated to time, place and person. He had a temperature
of 38.4 degree Celsius, blood pressure of 140/90 mmHg,
pulse rate of 80 per minute and respiratory rate of 16 per
minute. His respiratory examination revealed reduced
chest expansion over the left lung base associated with
dullness to percussion, bronchial breath sounds and
crackles. His cardiovascular, abdominal and neurological
examination was unremarkable. A chest radiograph con-
firmed consolidation in the left lower zone with milder air
space opacity in the right lower zone. He was initially di-
agnosed with healthcare associated pneumonia in view of
recent hospitalization and started on intravenous tazocin.
Respiratory viruses multiplex PCR (Polymerase Chain
Reaction) was negative.
On the fourth day of admission, he developed vesiculo-
papular pruritic lesions mainly over the trunk. Varicella
Zoster Virus (VZV) IgM was positive. He was isolated to-
gether with air-borne and contact precautions, and started
on oral Valacyclovir 500 mg daily later on that day. The. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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of the consolidation was noted on repeat chest radiograph.
He also developed vivid visual hallucinations, became rest-
less and agitated and disorientated to time, place and per-
son. A diagnosis of varicella zoster infection complicated
by varicella pneumonia and encephalitis was made. Vala-
cyclovir was switched to intravenous acyclovir. A lumbar
puncture showed increased protein and lymphocytes and
was negative for cryptococcal antigen and neurotropic vi-
ruses. A magnetic resonance imaging scan of the brain
showed no evidence of acute infarct, intracranial bleed,
space-occupying lesion or hydrocephalus. The frequency
of dialysis was increased with continuation of the renal ad-
justed dose of acyclovir.
Throughout the admission, his hemodialysis continued
and he completed 2 weeks of IV acyclovir. His functional
status improved back to the pre-morbid levels on discharge.
Discussion
The incidence of varicella in Singapore has been increasing
since 1984 [1] and increased from 14,999 in 2003 to 24,031
in 2006. Mandatory notification of varicella ceased since
27th August 2007 [2]. Thus the latest reported figures are
not known.
Primary infection with varicella is usually a benign and
self-limiting illness in immunocompetent children. How-
ever, patients with end stage renal failure have lympho-
cytopenia and impaired lymphocyte function and are
susceptible for disseminated varicella and its complications,
with more severe morbidity and mortality rates [3,4].
Our patient suffered severe complications of varicella
infection that is pneumonia and viral encephalitis. Other
known complications include myocarditis, corneal lesions,
nephritis, arthritis, bleeding diatheses, acute glomerulo-
nephritis, hepatitis and secondary bacterial superinfection
of the skin.
The central nervous system is the most common extra
cutaneous site of involvement, manifesting as acute cerebel-
lar ataxia or diffuse encephalitis. These disorders typically
develop toward the end of the first week of the exanthem,
but can also precede the rash [5,6]. Diffuse encephalitis
most often occurs in adults and clinical manifestations in-
clude delirium, seizures, loss of consciousness and focal
neurological signs including cranial nerve palsies, hemipar-
esis. Varicella encephalitis is more severe in immunosup-
pressed hosts who typically have a fulminant course with
seizures, mental status changes and focal deficits including
stroke syndromes. However very little data exist regarding
the occurrence of varicella encephalitis in patients with end
stage renal failure or those undergoing dialysis.
In the workup for VZV encephalitis, computed tomog-
raphy or magnetic resonance imaging may or may not
demonstrate abnormal radiographic findings, although elec-
troencephalography is often abnormal in acute encephalitis.The cerebrospinal fluid contains lymphocytes and elevated
levels of protein but normal glucose concentration, allow-
ing differentiation from bacterial meningitis. Cerebrospinal
fluid polymerase chain reaction (CSF PCR) can be used to
detect VZV DNA, and has a specificity of greater than 95%,
but the sensitivity is 30% or less in some studies [7]. Re-
peated mortality rates approach 10% and long-term neuro-
logic sequelae are reported in up to 15% of survivors [8-10].
There is no proven effective therapy once encephalitis oc-
curs, and supportive care remains the mainstay of manage-
ment. Acyclovir has been used with anecdotal success
[11-13]. However, acyclovir neurotoxicity should always be
considered in patients with prolonged or worsening neuro-
logical symptoms.
Varicella pneumonia is the most serious complication
following varicella, develops more commonly in adults
(up to 20% of cases) than in children, and accounts for
the majority of morbidity and mortality seen in adults
with varicella [11]. Risk factors linked to the develop-
ment of varicella pneumonia include cigarette smoking,
pregnancy and an immunosuppressed state [9]. Varicella
pneumonia typically develops insidiously with symptoms
of progressive dyspnea and dry cough. Patients demon-
strate impaired gas exchange with progressive hypox-
emia and are at high risk for respiratory failure and need
for admission to intensive care for mechanical ventila-
tion [14,15]. Mortality rates approach 50% in patients
with respiratory failure who require mechanical ventilation,
despite institution of aggressive therapy and appropriate
support measures [16,17]. Chest radiographs typically re-
veal diffuse bilateral infiltrates. Prompt administration of
intravenous acyclovir has been associated with clinical im-
provement and resolution of pneumonia in selected series
[17,18]. Resolution of pneumonitis parallels improvement
of the skin rash, although fever and compromised pulmon-
ary function may persist for weeks [11]. The use of steroids
as adjunctive therapy for treatment of life-threatening vari-
cella pneumonia is still controversial and should be further
examined in rigorous controlled trials [19].
In immunosuppressed hosts such as ESRF patients or
immunocompetent patients with disseminated disease such
as pneumonia or encephalitis, varicella should be treated
with IV acyclovir [20]. IV acyclovir reduces the occurrence
of visceral complications but has no effect on healing of
skin lesions or pain [11]. The recommended dose is 10 mg/
kg Q8h for 7 days.
In December 2012, the FDA approved varicella zoster
immune globulin (VariZIG) for administration to high
risk individuals within 4 days of varicella exposure.
Acyclovir is an effective agent for the treatment of VZV
infections but renal impairment results in high serum
drug levels with resultant neurotoxicity. In renal failure,
the half-life of acyclovir is increased from a maximum of
3.8 to 20 hours, and dosage reduction is required using
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tration of recommended reduced doses can result in
high serum levels and neurotoxicity, due to poor removal
of acyclovir by peritoneal dialysis [4]. Tremors, disorienta-
tion, agitation, hallucinations, and delirium are common
presentations of acyclovir-induced encephalopathy, whereas
seizures, cerebellar ataxia, sensory symptoms, speech disor-
ders, fever and cranial nerve palsies are much less frequent.
Features distinguishing acyclovir neurotoxicity from VZV
encephalitis include a temporal association between the
symptoms and acyclovir use, as well as acellular CSF exam-
ination. However, acyclovir neurotoxicity should always
be considered in patients with prolonged or worsening
neurological symptoms for which daily hemodialysis is
required often.
Studies show that many ESRF and kidney transplant pa-
tients do not have immunity to varicella [22-25]. Primary
varicella infection is common, up to 1.9% of renal
transplant recipients are admitted in the first year post-
transplant [26]. The infection can have serious compli-
cations and be lethal in these ESRF and renal transplant
patients who are immunosuppressed [24,26-29].
Live attenuated varicella vaccine is generally contraindi-
cated in immunosuppressed patients but has been proven
to be safe when administered to both pediatric [23,24,29]
and adult end stage renal failure patients on dialysis, [27]
as well as renal transplant patients on immunosuppressive
treatment [25].
Despite the general suppression of the immune system
associated with uremia, patients with ESRF have high
seroconversion rates to a two-dose varicella vaccination
regimen. Seroconversion rates ranged from 87-100%
[23,29-31] in ESRF pediatric patients waiting for transplant
and 64% in adult ESRF patients [24]. 66.6% of pediatric
renal transplant recipients seroconverted after a one–two
dose varicella vaccination regimen [25]. Immunization
guidelines in New Zealand recommend a two dose vari-
cella vaccination regimen for children with deteriorating
renal function, as early as possible before transplantation
[32]. In the United States, the Centers for Disease Control
and Prevention (CDC) adult immunization schedule rec-
ommend a two dose varicella vaccination regimen and a
single dose zoster vaccination for patients with ESRF and
recipients of hemodialysis [33,34]. However, ESRF patients
have an inability to maintain adequate antibody titers over
time [35,36]. Reports describe several patients in whom im-
munity to varicella waned in chronic renal insufficiency and
in the post-transplant period [26,27]. Hence there is a need
for yearly surveillance of antibody titre as are done for
Hepatitis B & C virus and cytomegalovirus. Special consid-
eration for vaccination should also be given to persons who
have close contact with or are at high risk of transmission
to ESRF patients [32]. Although there are recommendations
to administer varicella immunoglobulin to transplantpatient coming in contact with varicella patients [37], the
use of immunglobulins has risks and is expensive. Immuno-
globulins should be reserved for those with imminent ex-
posure to the virus. Varicella vaccination is a cheaper and
more effective way for prevention of varicella.
Role of family physicians
There were 4,169 patients on dialysis in Singapore by 2008.
This number represented a 89% increase since end 1998,
when there were 2,209 patients on dialysis. The incidence
of new ESRF patients requiring dialysis increases every
year, from 564 new cases in 1998 to 1,212 cases in 2008.
This represents a 115% increase during this 10-year period
[38-40]. In addition, patients are getting more elderly. In
2006, 52.1% and 5.1% of incident dialysis patients were
over the age of 60 and 80 respectively. With a rapidly age-
ing population, Singapore can expect an increasing burden
of end stage renal disease Family physicians should advise
their ESRF patients of the life-threatening complications of
varicella and urgent need for review if they develop fever
or rash after coming in contact with varicella patients.
Currently, there are no local data on the seropositivity
against varicella antibody in ESRF patients in Singapore
or consensus guidelines for varicella vaccination. With an
increasing burden of chronic kidney disease, Renal Physi-
cians and Family Physicians in the Asia-Pacific region
should meet and study the epidemiological data in each
individual country and decide on consensus guidelines
and how the varicella vaccination program can be targeted
for those at risk. Research on the seroprevalence of vari-
cella in ESRF patients should be conducted if such data is
not currently available in Asia-Pacific countries.
Conclusions
Evidence supports the safety and efficacy of varicella vac-
cination in patients with end stage renal failure. Guidelines
for varicella vaccination for ESRF patients are available in a
few countries [33,34]. The intent of our paper is to stimu-
late more research in the area of generating the need of
consensus guidelines for universal vaccinations of ESRF pa-
tients on dialysis. Serious consequences of primary varicella
infection can be avoided with appropriate vaccinations.
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